Reuters logo
BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA
2017年10月18日 / 上午11点14分 / 1 个月前

BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA

Oct 18 (Reuters) - Merck & Co Inc

* Merck’s KEYTRUDA® (pembrolizumab) more than doubled median overall survival compared to chemotherapy after two years of follow up in first-line treatment of patients with metastatic non-small cell lung cancer with high levels of PD-L1

* Merck & Co Inc - ‍data from study showed median overall survival of 30.0 months for KEYTRUDA group compared to 14.2 months for chemotherapy group​

* Merck & Co Inc - ‍safety of KEYTRUDA was consistent with what has been seen in previous trials among patients with metastatic NSCLC​

* Merck - ‍results continue to show reduction in risk of death by 37 percent for KEYTRUDA versus chemotherapy based on more than two years of median follow-up​

* Merck & Co - ‍ announced presentation of updated overall survival findings, secondary endpoint, from Phase 3 KEYNOTE-024 trial evaluating keytruda​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below